Global Sexually Transmitted Diseases Diagnostics (STD) Market Growth 2025 | Expanding PCR, POC & Immunoassay Technologies to 2033

Global Sexually Transmitted Diseases (STD) diagnostics market reached US$ 10.6 billion in 2024 and is expected to reach US$ 19.4 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/sexually-transmitted-diseases-diagnostics-market?kb

United States - Recent Industry Developments

✅ November 2025: Abbott expanded rapid point-of-care STD diagnostic panels across community health centers to improve early detection.

✅ October 2025: Quest Diagnostics introduced enhanced multiplex PCR-based tests enabling simultaneous screening of multiple STDs.

✅ September 2025: CDC partnered with diagnostic manufacturers to broaden access to home-based self-sampling STD kits nationwide.

Japan - Recent Industry Developments

✅ November 2025: Sysmex Corporation launched advanced chemiluminescent assays to detect syphilis and chlamydia with higher sensitivity.

✅ October 2025: Fujifilm collaborated with hospitals to integrate AI-assisted interpretation in STD diagnostics workflow.

✅ September 2025: Rising adoption of telehealth-supported STI testing kits among young adults accelerated demand for at-home diagnostics.

GCC - Recent Industry Developments

✅ November 2025: UAE Ministry of Health approved expanded rapid STD screening programs across private and public healthcare facilities.

✅ October 2025: Saudi Arabia began deploying molecular PCR platforms to strengthen STD testing accuracy across major hospitals.

✅ September 2025: Qatar initiated awareness and screening campaigns promoting preventive STD testing supported by mobile diagnostic vans.

List of Top Key Player:

Abbott Laboratories, Becton, Dickinson, and Company, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Hologic, Inc., QIAGEN N.V., Diasorin S.p.A., Seegene Inc., Bosch Healthcare Solutions GmbH

Latest M&A in STD diagnostics

1. Most recent deal activity is in molecular/self‐testing platforms that include STD menus, especially chlamydia/gonorrhea and HIV.

2. OraSure Technologies' USD 1.5 billion acquisition of Sherlock Biosciences (Dec 2024, impact through 2025) significantly expands OraSure's molecular self‐testing capabilities, including a CT/NG (chlamydia/gonorrhea) self‐test currently in clinical studies and expected to be filed with FDA by end‐2025.​

3. Industry reviews highlight ongoing acquisitions and partnerships by firms like Hologic and bioMérieux to bring faster, more accurate NAAT‐based STD assays into their portfolios, reflecting a broader trend toward molecular consolidation in STI testing.

Forecast Projection:

The Global Sexually Transmitted Diseases Diagnostics Market is poised for significant growth between 2025 and 2033. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Technology and pipeline in STD diagnostics

1. Diagnostics innovation focuses on speed, multiplexing, and point‐of‐care.

2. Molecular diagnostics for STDs (especially NAATs) are growing rapidly, with the molecular STD diagnostics segment alone estimated at about USD 3.4 billion in 2024 and on track to almost double by early 2030s.​

3. Multiplex platforms and ELISAs that can detect several infections (e.g., chlamydia plus other STIs from a single sample) are being developed, improving lab efficiency and reducing cost per diagnosis.​

4. Point‐of‐care and home/self‐collection are major growth drivers: forecasts emphasize "low‐touch" and decentralized STD testing, AI‐assisted result interpretation, and microfluidic devices that improve home‐sample accuracy

Market Intelligence Research Process:

The Global Sexually Transmitted Diseases Diagnostics Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=sexually-transmitted-diseases-diagnostics-market?kb

Key Segments:

By Product Type: (Instruments, Consumables, Software)

By Disease Type: (Chlamydia, Genital Herpes, Gonorrhea, Hepatitis B, HIV/AIDS, Human papillomavirus (HPV), Syphilis and Others)

By Diagnostic Test Type: (Molecular Tests, Serologic Tests, Point-of-Care (PoC) Tests and Others)

By End-User: (Hospitals, Specialty Clinics, Diagnostic Laboratories, Homecare Settings and Others)

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Global Sexually Transmitted Diseases Diagnostics Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/sexually-transmitted-diseases-diagnostics-market?kb

FAQ's

Q1: What is the current size of the Global Sexually Transmitted Diseases Diagnostics Market and its future potential?

A: The Global Sexually Transmitted Diseases Diagnostics Market was valued at US$ 10.6 billion in 2024 and is projected to surge to US$ 19.4 billion by 2033

Q2: How fast is the Global Sexually Transmitted Diseases Diagnostics Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 7.1% between 2025 and 2033

Q3: Which regions are dominating the Global Sexually Transmitted Diseases Diagnostics Market and which are fastest-growing?

A: Key markets include North America, Europe, and Asia-Pacific, led by the U.S., Japan, China, and Germany.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Latest and notable drugs relevant to STIs

1. While classical "STD drugs" (e.g., for chlamydia, gonorrhea, syphilis) rely mostly on established antibiotics, there are two important recent HIV‐related developments within the STI arena.

2. Yeztugo (lenacapavir) - In June 2025, the U.S. FDA approved Yeztugo, a long‐acting injectable HIV pre‐exposure prophylaxis (PrEP) option, the first twice‐yearly injectable PrEP regimen and a major shift in HIV prevention.​

3. Doravirine/islatravir - In December 2025, FDA accepted Merck's NDA for doravirine/islatravir, a once‐daily, two‐drug oral regimen for virologically suppressed adults with HIV‐1; if approved, it will be the first non‐integrase two‐drug switch option, further expanding chronic HIV treatment choices.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

This release was published on openPR.